The introduction of B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell therapy (CAR-T) in clinical practice has radically shifted the treatment paradigm of relapsed/refractory multiple myeloma (RRMM). Here, TNFRSF17 is linked to plasma cell myeloma.